Ethanethiol, 2-amino-,1-(dihydrogen phosphate), sodium salt (1:1) structure
|
Common Name | Ethanethiol, 2-amino-,1-(dihydrogen phosphate), sodium salt (1:1) | ||
|---|---|---|---|---|
| CAS Number | 3724-89-8 | Molecular Weight | 179.11000 | |
| Density | 1.597g/cm3 | Boiling Point | 384.2ºC at 760mmHg | |
| Molecular Formula | C2H7NNaO3PS | Melting Point | 220ºC (dec.)(lit.) | |
| MSDS | Chinese USA | Flash Point | 186.2ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of Ethanethiol, 2-amino-,1-(dihydrogen phosphate), sodium salt (1:1)Cysteamine S-phosphate (Cystaphos) sodium can be hydroIyzed to Cysteamine by human alkaline phosphatases. Cysteamine is an orally active agent for the research of nephropathic cystinosis and an antioxidant[1][2]. |
| Name | sodium,2-aminoethylsulfanyl(hydroxy)phosphinate |
|---|---|
| Synonym | More Synonyms |
| Description | Cysteamine S-phosphate (Cystaphos) sodium can be hydroIyzed to Cysteamine by human alkaline phosphatases. Cysteamine is an orally active agent for the research of nephropathic cystinosis and an antioxidant[1][2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.597g/cm3 |
|---|---|
| Boiling Point | 384.2ºC at 760mmHg |
| Melting Point | 220ºC (dec.)(lit.) |
| Molecular Formula | C2H7NNaO3PS |
| Molecular Weight | 179.11000 |
| Flash Point | 186.2ºC |
| Exact Mass | 178.97800 |
| PSA | 121.49000 |
| LogP | 0.90950 |
| InChIKey | VZEGNYNPDZDIRW-UHFFFAOYSA-M |
| SMILES | NCCSP(=O)([O-])O.[Na+] |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | 22-36/37/38 |
| Safety Phrases | S26;S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | TE6483500 |
|
A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis.
Pediatr. Res. 23(6) , 616-20, (1988) Cysteamine (beta-mercaptoethylamine, MEA) is currently used to treat children with nephropathic cystinosis. In this study MEA was compared to phosphocysteamine (MEAP), a phosphorothioester that tastes... |
|
|
The treatment of cystinosis with cysteamine and phosphocysteamine in the United Kingdom and Eire.
Pediatr. Nephrol. 9(6) , 685-9, (1995) Fifty-nine patients with cystinosis were treated with cysteamine or phosphocysteamine in the United Kingdom up to May 1990. Treatment was started at a median age of 3.2 years (range 0.6-24.8 years) an... |
|
|
Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis.
J. Inherit. Metab. Dis. 35(5) , 847-57, (2012) Infantile neuronal ceroid lipofuscinosis (INCL) is a profoundly neurodegenerative disease of children caused by a deficiency in the lysosomal enzyme palmitoyl protein thioesterase-1 (PPT1). There is c... |
| Phosphocysteamine |
| Tsistafos |
| MFCD00038474 |
| Cystaphos sodium salt |
| Tsistafos (cystafos) |
| Cystaphos |
| Cistaphos |
| S-(2-Aminoethyl) thiophosphate monosodium salt |
| EINECS 223-079-5 |
| Cystafos |